并购对赌变“毒药”：*ST恒久三年造假链与资本市场的血色警示

Group 1 - The core issue revolves around Suzhou Hengjiu Optoelectronics Technology Co., Ltd. facing severe penalties for financial fraud over three consecutive years, revealing a distorted ecosystem under the A-share market's merger performance betting mechanism [1][2] - The company inflated profits by over 70 million yuan from 2019 to 2021 through fraudulent activities, including falsifying project acceptance materials and creating fictitious contracts [1][2] - In 2020, the inflated profit reached 38.6 million yuan, accounting for 103.96% of the disclosed profit, while in the first half of 2021, the inflated profit percentage soared to 123.56%, masking actual losses [1][2] Group 2 - The fraud was orchestrated by the general manager of the acquired subsidiary, who led a systematic deception involving multiple fabricated contracts and financial flows [2] - The internal control system of Hengjiu Technology was severely lacking, with the financial director ignoring anomalies and the audit committee members signing off on false annual reports [3] - Despite the exposure of the fraud and ongoing losses, the company's stock price surged by 70% in April and May 2025 due to speculative trading, highlighting a disconnect between market performance and financial health [3]